• Takeda will present research at the American Society of Hematology annual meeting in New Orleans, December 12-15, 2026.
• New analyses show Mimrylo reduced symptoms and treatment burden in polycythemia vera; the drug has FDA clearance for adults with the disease.
• Phase 2 elritercept data suggest potential for durable responses and improved quality of life in patients with lower-risk myelodysplastic syndrome.
• A post hoc Phase 2 mezagitamab analysis links higher platelet counts to better quality of life in persistent or chronic immune thrombocytopenia.
• Elritercept and mezagitamab remain investigational, with neither authorized by any health authority.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.